



Cumberland Emerging Technologies Enters into a Collaboration Agreement with Washington University in St. Louis

NASHVILLE, Tenn. (August 22, 2011)- Cumberland Emerging Technologies, Inc. (CET) has entered into a Collaboration Agreement with Washington University to co-develop promising biomedical technologies. Located in St. Louis, Washington University is a national leader in medical research and ranks among the top 10 U.S. institutions for research funded by the National Institutes of Health (NIH).

Under the terms of this agreement, CET and Washington University will hold annual meetings to review novel technologies originating within the academic laboratories and advance progress for existing collaborative projects. Currently, CET has one collaborative development program underway with the University to evaluate a radio protective drug product indicated for cancer patients.

This collaboration agreement represents the fourth major university partnership for CET, which has similar arrangements with Vanderbilt University, the University of Tennessee Patent Foundation and the University of Mississippi. These agreements provide CET and Cumberland Pharmaceuticals Inc. access to promising pipeline candidates such as Hepatoren[®], Cumberland's newest portfolio addition. Collaboration with academic partners provides a means for Cumberland to have a role in fostering and shaping early-stage biomedical research towards creating new products that improve patient care.

About Cumberland Emerging Technologies Inc.

Cumberland Emerging Technologies Inc. (CET) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc., and the Tennessee Technology Development Corporation (TTDC). The mission of CET is to advance biomedical technologies and products conceived at academic research centers towards the commercial marketplace. CET manages the development and commercialization process for select projects, and provides critical expertise on intellectual property, regulatory, manufacturing, and market issues that are critical to successful new biomedical products.

CET has sponsored Middle Tennessee's first life sciences incubator located in downtown Nashville adjacent to the Union Station Hotel and the Frist Visual Arts Center. This Life Sciences Center provides laboratory space, equipment and other support to a growing number of tenants who specialize in medical products and research advancements. For more information, visit www.CET-Fund.com.